

Tablica 10. Prvih 30 lijekova po financijskoj potrošnji izraženo u kunama, BOLNIČKA POTROŠNJA u 2019. godini

RBR	ATK	INN	UKUPNI IZNOS
1	L01XC18	pembrolizumab	169.380.446
2	L01XC07	bevacizumab	99.591.530
3	L01XC03	trastuzumab	91.408.514
4	M09AX07	nusinersen	80.984.209
5	L01XC13	pertuzumab	79.685.983
6	L01XC02	rituksimab	65.916.329
7	L01XE27	ibrutinib	61.751.046
8	J06BA02	imunoglobulini, humani, za i.v. primjenu	61.488.207
9	L02BB04	enzalutamid	50.663.209
10	J05AP57	glekaprevir, pibrentasvir	49.744.396
11	L01XC24	daratumumab	47.553.777
12	L04AX04	lenalidomid	47.021.450
13	L01XX32	bortezomib	45.846.319
14	L01XC17	nivolumab	45.261.534
15	L04AB02	infliksimab	42.817.544
16	B05BB01	elektroliti	42.377.818
17	L02BX03	abirateron	40.977.113
18	L01XE33	palbociklib	40.665.746
19	L01XE42	ribociklib	40.296.110
20	L01XE08	nilotinib	37.701.710
21	L04AC07	tocilizumab	30.144.905
22	L01CD01	paklitaksel	29.870.860
23	L04AB04	adalimumab	29.826.538
24	B05AA01	albumin, ljudski	27.917.025
25	B01AB05	enoksaparin	27.823.761
26	L01XE04	sunitinib	27.602.831
27	L04AC05	ustekinumab	26.702.831
28	J05AP55	sofosbuvir i velpatasvir	26.200.120
29	A16AB02	imigluceraza	25.343.305
30	H01CB02	oktreotid	24.529.174